When was Artiva founded?

Artiva was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Artiva located?

Artiva is headquartered in San Diego, United States. It is registered at Rīga, Sila iela 9.

How many employees does Artiva have?

As of Jul 31, 2026, the latest employee count at Artiva is 112.

Is Artiva a funded company?

Artiva is a funded company, having raised a total of $198M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 2019.

When was the latest funding round of Artiva?

Artiva's latest funding was a $***** Series B round on Feb 22, 2021, with participation from 15 investors.

What is the annual revenue of Artiva?

Annual revenue of Artiva is less than $1M as on Dec 31, 2024

Where does Artiva rank among its competitors?

Artiva ranks 488th amongst 3293 active competitors, of which 1119 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Artiva?

Artiva's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Artiva - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics for autoimmune diseases and cancer. The product pipeline includes AB-101 is an ADCC enhancer for B-cell malignancies, AB-201 and AB202 are targeted CAR-NK are allogeneic NK cell therapies that work on innate biology and enhance the efficacy through antibody combination therapy and genetic engineering.

Website: artivabio.com
Social
Email ID: *****@artivabio.com
Phone Number: +1 **********
Registered Address: Rīga, Sila iela 9

Key Metrics

Founded Year

2018

Location

San Diego, United States

Stage

Public

Total Funding

$198M in 3 rounds

Latest Funding Round

Series B, Feb 22, 2021, $*****

Investors

Venrock & 16 more

Ranked

488^th among 3293 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2024

Employee Count

112 as on Jul 31, 2026

Similar Companies

Senti Bio & 150 more

Exit Details

Public

View Artiva's full profile

Artiva is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ARTIVA BIOTHERAPEUTICS, INC. CIN: 32069811928 , United States, Active	Feb 20, 2019	$0 - $1M (As on Dec 31, 2024)	-	-
Artiva Biotherapeutics, Inc CIN: 833614316 , United States, Active	Feb 19, 2019	-	86 (As on Dec 31, 2024)	-
ARTIVA CIN: 40003530849 , Latvia, Active	Feb 07, 2001	€0 - €1M (As on Dec 31, 2024)	5 (As on Dec 31, 2022)	-

Artiva got listed on Jul 19, 2024.

Click here to take a look at Artiva's IPO in detail

Artiva has raised a total funding of $198M over 3 rounds. Its first funding round was on Feb 2019. Its latest funding round was a Series B round on Feb 22, 2021 for $*****. 15 investors participated in its latest round. Artiva has 17 institutional investors.

Here is the list of recent funding rounds of Artiva:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 22, 2021	8255849	Series B	8945635	5176711	1575060	8795538
Jun 26, 2020	9928685	Series A	1644322	5245021	1440037	Medivate Partners & 1 more
Feb 2019	3132129	Seed	4073671	1381127	8699265	GC Green Cross Lab Cell

Access funding benchmarks and valuations. Sign up today!

View details of Artiva's funding rounds and investors

Artiva's employee count trend

Artiva has 112 employees as of Jul 26. Here is Artiva's employee count trend over the years:

Uncover Artiva's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Artiva include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Artiva, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
488th	Artiva 2018, San Diego (United States), Public	Developer of therapeutics for autoimmune diseases and cancer	$198M	RTW Investments, VenBio & 15 others	53/100